Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 12/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493336 | 0.87 | ALKBH5 (0.61) | ALKBH5FTOMAPTMEN1KMT2A | |
| SCHEMBL1493267 | 0.87 | ALKBH5 (0.51) | ALKBH5FTOMAPTMEN1KMT2A | |
| SCHEMBL1493314 | 0.86 | MAPT (0.63) | ALKBH5FTOMAPTALDH1A1 | |
| SCHEMBL1493371 | 0.86 | ALKBH5 (0.63) | ALKBH5FTOMAPTMEN1KMT2A | |
| SCHEMBL1493265 | 0.82 | ALKBH5 (0.53) | ALKBH5FTOMAPT | |
| SCHEMBL1493335 | 0.79 | MAPT (0.45) | ALKBH5FTOMAPT | |
| SCHEMBL30512046 | 0.78 | ALKBH5 (0.85) | ALKBH5FTOMAPTALDH1A1 | |
| SCHEMBL30512076 | 0.76 | ALKBH5 (0.61) | ALKBH5FTOMAPTMEN1KMT2A | |
| SCHEMBL30512071 | 0.76 | MAPT (0.67) | ALKBH5FTOMAPTALDH1A1KIT | |
| SCHEMBL1493316 | 0.76 | KIT (0.46) | MAPTMEN1KMT2AALDH1A1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ALKBH5 4874/4885FTO 4701/4885MAPT 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.